两个美国医疗系统中慢性肾脏病患者表观治疗抵抗性高血压的患病率
研究纳入Kaiser Permanente南加州和退伍军人健康管理局中eGFR<60 ml/min per 1.73 m2且接受高血压治疗的成人CKD患者,按2017 ACC/AHA和2021 KDIGO指南定义估算表观治疗抵抗性高血压患病率。结果显示,按2017 ACC/AHA指南,Kaiser Permanente南加州为39%、退伍军人健康管理局为35%;按2021 KDIGO指南分别为48%和55%;要求利尿剂后患病率降低。CKD分期越晚患病率越高,最高达一半患者符合表观治疗抵抗性高血压标准。
要点
- 按2017 ACC/AHA指南,表观治疗抵抗性高血压患病率在Kaiser Permanente南加州为39%、退伍军人健康管理局为35%。
- 按2021 KDIGO指南,患病率分别为48%和55%。
- 要求利尿剂后,按2017 ACC/AHA指南患病率降至31%和23%。
核心结论
- 根据CKD分期,高达一半的CKD患者符合表观治疗抵抗性高血压标准。
研究设计与样本
- 研究纳入Kaiser Permanente南加州和退伍军人健康管理局中eGFR<60 ml/min per 1.73 m2且接受高血压治疗的成人CKD患者,共44,543例和241,465例。
- 使用电子健康记录识别表观治疗抵抗性高血压:血压高于目标值且使用≥3类降压药,或使用≥4类降压药 regardless of BP。
- 敏感性分析要求使用利尿剂才归类为表观治疗抵抗性高血压。
- 按临床指南和CKD分期估算表观治疗抵抗性高血压患病率。
主要发现
- 按2017 ACC/AHA指南,表观治疗抵抗性高血压患病率在Kaiser Permanente南加州为39%、退伍军人健康管理局为35%。
- 按2021 KDIGO指南,患病率在Kaiser Permanente南加州为48%、退伍军人健康管理局为55%。
- 要求利尿剂后,按2017 ACC/AHA指南患病率降至Kaiser Permanente南加州31%、退伍军人健康管理局23%。
- 按2017 ACC/AHA指南,eGFR 45-59、30-44、15-29和<15 ml/min per 1.73 m2的患病率分别为Kaiser Permanente南加州34%/33%、42%/36%、52%/41%和60%/37%(Kaiser Permanente南加州/退伍军人健康管理局)。
关键数值与推荐
- 2017 ACC/AHA指南:血压目标<130/80 mm Hg。
- 2021 KDIGO指南:收缩压目标<120 mm Hg。
- 表观治疗抵抗性高血压定义:血压高于目标值且使用≥3类降压药,或使用≥4类降压药 regardless of BP。
- 敏感性分析定义:要求使用利尿剂。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: More intensive BP goals have been recommended for patients with CKD. We estimated the prevalence of apparent treatment-resistant hypertension among patients with CKD according to the 2017 American College of Cardiology/American Heart Association (ACC/AHA; BP goal <130/80 mm Hg) and 2021 Kidney Disease Improving Global Outcomes (KDIGO; systolic BP <120 mm Hg) guidelines in two US health care systems. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We included adults with CKD (an eGFR <60 ml/min per 1.73 m2) and treated hypertension from Kaiser Permanente Southern California and the Veterans Health Administration. Using electronic health records, we identified apparent treatment-resistant hypertension on the basis of (1) BP above the goal while prescribed three or more classes of antihypertensive medications or (2) prescribed four or more classes of antihypertensive medications regardless of BP. In a sensitivity analysis, we required diuretic use to be classified as apparent treatment-resistant hypertension. We estimated the prevalence of apparent treatment-resistant hypertension per clinical guideline and by CKD stage. RESULTS: Among 44,543 Kaiser Permanente Southern California and 241,465 Veterans Health Administration patients with CKD and treated hypertension, the prevalence rates of apparent treatment-resistant hypertension were 39% (Kaiser Permanente Southern California) and 35% (Veterans Health Administration) per the 2017 ACC/AHA guideline and 48% (Kaiser Permanente Southern California) and 55% (Veterans Health Administration) per the 2021 KDIGO guideline. By requiring a diuretic as a criterion for apparent treatment-resistant hypertension, the prevalence rates of apparent treatment-resistant hypertension were lowered to 31% (Kaiser Permanente Southern California) and 23% (Veterans Health Administration) per the 2017 ACC/AHA guideline. The prevalence rates of apparent treatment-resistant hypertension were progressively higher at more advanced stages of CKD (34%/33%, 42%/36%, 52%/41%, and 60%/37% for Kaiser Permanente Southern California/Veterans Health Administration eGFR 45-59, 30-44, 15-29, and <15 ml/min per 1.73 m2, respectively) per the 2017 ACC/AHA guideline. CONCLUSIONS: Depending on the CKD stage, up to a half of patients with CKD met apparent treatment-resistant hypertension criteria.
引用
- An J, Kurella Tamura M, Odden MC, et al. Prevalence of Apparent Treatment-Resistant Hypertension in Chronic Kidney Disease in Two Large US Health Care Systems. Clin J Am Soc Nephrol. 2022. PMID: 36400564. doi:10.2215/CJN.04110422
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。